18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nuclear Medicine Communications 2011, 32: 343-347. PMID: 21412178, DOI: 10.1097/mnm.0b013e328344894b.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArea Under CurveBevacizumabColorectal NeoplasmsFemaleFluorine RadioisotopesFluorodeoxyglucose F18FluorouracilHumansMaleMiddle AgedPilot ProjectsPositron-Emission TomographyRadiopharmaceuticalsTomography, Emission-ComputedConceptsPET/CT scanningPositron emission tomography/Emission tomography/CT scanningTomography/Standardized uptake value analysisPilot studyStable tumor sizeMetastatic colorectal adenocarcinomaMetastatic colorectal cancerMetastatic colorectal carcinomaAdministration of bevacizumabPresence of cancerDynamic positron emission tomography/Metastasis sizeInjection of radiotracerColorectal metastasesMetastatic lesionsMetastatic sitesTumor sizeColorectal cancerColorectal adenocarcinomaColorectal carcinomaHistopathological analysisRadiotracer uptake